Literature DB >> 24967155

First case report of bloodstream infection by Rhizomucor pusillus in a child with hemophagocytic lymphohistiocytosis.

Jennifer Dien Bard1, Aida Mangahis2, Thomas C Hofstra3, Jeffrey M Bender4.   

Abstract

We describe an unusual presentation of fatal infection due to Rhizomucor pusillus bloodstream infection in a 12-year old pediatric patient recently diagnosed with hemophagocytic lymphohistiocytosis. R. pusillus was isolated from one blood culture drawn on Day 11 of hospitalization.

Entities:  

Keywords:  Blood culture; Fungemia; Mucormycosis; Rhizomucor

Year:  2014        PMID: 24967155      PMCID: PMC4066188          DOI: 10.1016/j.mmcr.2014.05.002

Source DB:  PubMed          Journal:  Med Mycol Case Rep        ISSN: 2211-7539


Introduction

Mucormycosis is a life-threatening fungal infection caused by fungi of the order Mucorales. Members of the Mucoraceae family within the order Mucorales that are implicated in human disease are the Rhizopus, Mucor, Lichtheimia, Rhizomucor and Apophysomyces species [1]. These fungi are ubiquitous in soil, decaying vegetation, manure and food. Infections in patients are most commonly a result of aerosolization of the spores, leading to invasion of tissue from the respiratory tract. Gastrointestional infections have also been reported due to ingestion of contaminated food [2]. In the immunocompromised host, mucormycosis is the second most common mold infection and increase in prevalence has been particularly evident in hematopoietic stem cell transplant (HSCT) and hematologic malignancy patients [3]. Contrary to other filamentous fungal pathogens, mucormycosis can be rapidly progressive and fatal in immunocompetent hosts as well, including individuals with diabetes mellitus [4] and intravenous drug users [5]. The risk factors attributed to invasive mucormycosis are generally similar among adult and pediatric population; major clinical characteristics include neutropenia, diabetes mellitus, bone marrow transplantation, and ketoacidosis. A major underlying cause of co-morbid condition seen in pediatric patients with mucormycosis is prematurity. Prematurity is significantly associated with gastrointestional and cutaneous disease whereas clinical presentation seen in older children is more commonly pulmonary or sinuorbitaocerebral [6]. Common clinical patterns of mucormycosis in pediatric patients are cutaneous, gastrointestinal, rhinocerebral and pulmonary [7]. The signs, symptoms, and radiographic findings of mucormycosis are generally non-specific, and direct identification of the characteristic hyphae or recovery of the organism in culture is required for definitive diagnosis. The sensitivity and time to detection of conventional diagnostic tools remain suboptimal. This is particularly evident in the low recovery rate of Mucorales from blood cultures, despite the angioinvasive nature [8]. While automated blood culture systems have high recovery rates of bacteria and yeasts, recovery of most filamentous fungi from blood culture bottles is suboptimal and typically has no diagnostic value [9].

Case

A 12 year old girl with a history of hepatitis associated with Epstein Barr Virus (EBV) infection was presented to our institution (Day 0) with new onset fever and mild upper respiratory tract infection symptoms including cough and rhinorrhea. On examination, she was noted to have massive hepatomegaly and pallor. Initial labs were concerning for significant thrombocytopenia (platelet count of 32,000/uL), anemia (hemoglobin 6 g/dL, hematocrit 17%), evidence of liver failure (PTT>150 s, fibrinogen <40 mg/dL, albumin 2.2 g/dL, conjugated bilirubin 7.4 mg/dL, and AST 552 Units/L), elevated ferritin (21,300 ng/mL), and abnormal triglycerides (420 mg/dL). Her EBV viral load at presentation was >5,000,000 copies/mL. Studies for methicillin resistant Staphylococcus aureus colonization, cytomegalovirus, and hepatitis (A, B, and C) were all negative. The patient met the clinical definition for hemophagocytic lymphohistiocytosis (HLH) associated with EBV infection. On Day 2 of her admission, she experienced a generalized tonic–clonic seizure. She was intubated and required blood pressure support with continuous infusions of epinephrine and dopamine. At this time, she developed a fever to 39.4 °C. Two sets of blood cultures and urine cultures were drawn. Antibacterial coverage was initiated with piperacillin–tazobactam (400 mg/kg/day) and vancomycin (40 mg/kg/day). A computed tomography scan of her head with and without contrast was unremarkable. She was started on HLH 2004 modified protocol consisting of twice weekly etoposide and daily high-dose dexamethasone in an effort to bring her HLH under control. Femoral arterial and venous lines were placed. Over the next few days, she developed anuria requiring continuous renal dialysis support. Blood and urine cultures from the onset of her fever were negative. Vancomycin was discontinued, but piperacillin–tazobactam was continued throughout her hospital course. By Day 5 of admission, she was afebrile and no longer required epinephrine or dopamine for blood pressure support. Her absolute neutrophil count dropped to below 150 cells/μL where it remained through the remainder of her hospital course. She intermittently required platelet transfusions and cryoprecipitate for bleeding. She was on minimal ventilator settings and looked much improved over the next few days. The patient developed new low-grade fevers to 38.1 °C on Day 9 of hospitalization. Three sets of blood cultures were sent (2 from lines and 1 peripheral), all eventually were negative at Day 5. Clinically she appeared stable though she remained intubated and required continued dialysis. On Day 11 of admission, she acutely decompensated requiring maximal respiratory and blood pressure support. She developed profound hypothermia and bloody secretions from her endotracheal tube. Another aerobic blood culture was drawn. Before antibiotic coverage could be broadened, she experienced cardiac arrest and died despite resuscitation efforts. Family declined autopsy. Fungal growth was detected at 48 h from the aerobic blood bottle collected on Day 11 of admission using the BacT/Alert (bioMérieux, Marcy l׳Etoile, France) automated blood culture system. The system initially alarmed within 24 h but no organism was noted on Gram stain so bottle was subcultured onto blood agar and chocolate agar and placed back into the BacT/Alert. The bottle was flagged three more times over the next 24 h period and procedure was repeated; all subcultures were incubated at 35 °C in 5% CO2 and no growth was seen in all sets of plates. At Day 3 of incubation in BacT/Alert, probable fungal balls were visualized in the blood culture bottle (Fig. 1) and a few broad hyphae were seen using calcofluor white stain. The organism was subcultured to sabouraud agar and incubated at 30 °C in ambient air. Greyish-brown, velvety colonies grew after 48 h incubation and were transferred to potato dextrose agar. Thermotolerance test was performed and the isolate grew best at 42 °C and 35 °C followed by 30 °C but was unable to grow at 25 °C. Growth on media was atypical of the Zygomycetes where the colonies did not fill the agar plate, even at the preferential temperature of 42 °C (Fig. 2a). Slide cultures revealed a mold with large, non-septate hyphae, hyaline, branched sporangiophore (8–11 μm), subglobose, yellowish-brown sporangia approximately 70 μm in diameter, and subglobose columellae (20–35 μm); rhizoids were visualized but scarce (Fig. 2b). Based on microscopic morphology, organism was reported as Rhizomucor spp.
Fig. 1

BacT/Alert aerobic blood culture bottle. Demonstration of fungal balls growing after 72 h of incubation.

Fig. 2

(a) Macroscopic illustration of Rhizomucor pusillus. Preferential growth on potato dextrose agar after 48 h incubation at 42 °C. (b) Microscopic illustration of Rhizomucor pusillus. Presence of rare rhizoids on slide culture.

Definitive identification of the fungi was obtained by amplifying the internal transcribed spacer (ITS) 1 and 2 regions (ITS1 and ITS2) followed by bidirectional sequencing of the PCR product [10]. Resulting sequence were submitted to a GenBank Basic Local Alignment Search Tool software (BLAST) and >99% similarities to Rhizomucor pusillus [AJ853748] sequence was obtained. In addition, an ITS-BLAST search (www.mycologylab.org) also confirmed the GenBank result [WM 04.476]. The sequencing results correlated with the microbiological findings in the microbiology laboratory for R. pusillus.

Discussion

To our knowledge, there have only been two previously reported cases of mucormycosis diagnosed by positive blood culture [11,12]. Rhizopus rhizopodiformis was isolated from routine blood culture obtained post-mortem from one pediatric patient [11] and Mucor circinelloides was isolated from central venous catheter (CVC) line of a 48 year old patient with short gut syndrome [12]. While the majority of localized cutaneous mucormycosis cases are successfully resolved with anti-fungal agents, rare cases of disseminated mucomycosis are associated with high mortality [1,6,7]. In a review of 929 reported cases of mucormycosis, generalized dissemination occurred in 2.7% of cases with 100% mortality rate [1]. Moreover, timely treatment is pertinent to overall survival as rate in patients not treated with anti-fungal therapy was 3% compared to 70% survival rate in patients treated with anti-fungal and surgery. A multi-variate regression analysis of 157 pediatric patient cases demonstrates that risk of death is 7 times more likely in disseminated cases [6]. In this study, receipt of anti-fungal therapy significantly reduced risk of death by 92%. R. pusillus is a thermophilic saprophytic mucormycetes ubiquitous in air, soil, water and organic matter, including a variety of food items. R. pusillus is not commonly associated with human disease and typically occurs as opportunistic infections in susceptible hosts. Despite its low pathogenicity in humans compared to other agents of mucormycosis, R. pusillus is angioinvasive and thermotolerant, allowing for wide dissemination in febrile individuals [13]. To our knowledge, there have been 27 reported cases of R. pusillus related infections including pulmonary, soft tissue, rhino-orbital-cerebral, cerebral, intra-abdominal and disseminated infections; 25 out of the 27 patients (92.6%) had underlying conditions and overall mortality rate was 55.6%. 9 of the 26 reported cases were from the pediatric population, 7 of which had acute lymphoblastic leukemia, 1 had aplastic anemia, and 1 was immunocompetent [14-20]. Disease manifestations of the 9 cases were 3 disseminated, 2 rhinocerebral, 2 cutaneous, 1 pulmonary and 1 sinus-orbital case; 2 of the 3 patients with disseminated R. pusillus mucormycosis died [16,19,20]. Diagnosis of R. pusillus mucomycosis in all 9 patients was by direct culture of the site of infections and in the 3 disseminated cases, all blood cultures were negative. Our patient represents the third fatal case of R. pusillus bloodstream infection in the pediatric population and the first case of R. pusillus bloodstream infection diagnosed by positive blood culture. Due to the absence of autopsy, it is impossible to know definitively the etiology of the patient׳s R. pusillus infection. We suspect that infection spreads from primary pulmonary or abdominal infections and rapidly progressed to dissemination and death. Unfortunately, her clinical presentation was non-specific enough that invasive fungal infection was not thought to be part of her presentation until just prior to death. The fact that this mold grew in routine aerobic blood culture suggests a high burden of disease. This case emphasizes the importance of mucormycoses as severe and often fatal infections in immunocompromised patients. Though rare, Gram stain negative blood culture bottles that are flagging positive in this patient population may benefit from further evaluation, specifically looking for mucormycosis or other molds.

Conflict of interest statement

None.
  20 in total

1.  Zygomycosis: reemergence of an old pathogen.

Authors:  Carol A Kauffman
Journal:  Clin Infect Dis       Date:  2004-07-30       Impact factor: 9.079

2.  Multilocus DNA sequence comparisons rapidly identify pathogenic molds.

Authors:  Jennifer L Rakeman; Uyen Bui; Karen Lafe; Yi-Ching Chen; Rhonda J Honeycutt; Brad T Cookson
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

3.  Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis).

Authors:  Thomas J Walsh; Maria N Gamaletsou; Michael R McGinnis; Randall T Hayden; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2012-02       Impact factor: 9.079

4.  Disseminated Rhizomucor pusillus causing early multiorgan failure during hematopoietic stem cell transplantation for severe aplastic anemia.

Authors:  Neil J Rawlinson; Bonita Fung; Thomas G Gross; Amanda M Termuhlen; Micah Skeens; Amy Garee; Sandeep Soni; Daniel Pietryga; Rajinder P S Bajwa
Journal:  J Pediatr Hematol Oncol       Date:  2011-04       Impact factor: 1.289

5.  Mucormycosis in paediatric patients: demographics, risk factors and outcome of 12 contemporary cases.

Authors:  Jan Däbritz; Andishe Attarbaschi; Kathrin Tintelnot; Nina Kollmar; Bernhard Kremens; Friederike D von Loewenich; Lothar Schrod; Friedhelm Schuster; Uwe Wintergerst; Michael Weig; Thomas Lehrnbecher; Andreas H Groll
Journal:  Mycoses       Date:  2011-05-30       Impact factor: 4.377

Review 6.  Zygomycetes in human disease.

Authors:  J A Ribes; C L Vanover-Sams; D J Baker
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

7.  Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis.

Authors:  Greg T Siwek; Kirsty J Dodgson; Margarida de Magalhaes-Silverman; Luther A Bartelt; Sara B Kilborn; Peter L Hoth; Daniel J Diekema; Michael A Pfaller
Journal:  Clin Infect Dis       Date:  2004-07-30       Impact factor: 9.079

8.  Nosocomial infection by Rhizomucor pusillus in a clinical haematology unit.

Authors:  A del Palacio Hernanz; J Fereres; S Larregla Garraus; A Rodriguez-Noriega; F Sanz Sanz
Journal:  J Hosp Infect       Date:  1983-03       Impact factor: 3.926

Review 9.  Cerebral mucormycosis associated with intravenous drug use: three case reports and review.

Authors:  R J Hopkins; M Rothman; A Fiore; S E Goldblum
Journal:  Clin Infect Dis       Date:  1994-12       Impact factor: 9.079

Review 10.  Zygomycosis in children: a systematic review and analysis of reported cases.

Authors:  Theoklis E Zaoutis; Emmanuel Roilides; Christine C Chiou; Wendy L Buchanan; Tena A Knudsen; Tatyana A Sarkisova; Robert L Schaufele; Michael Sein; Tin Sein; Priya A Prasad; Jaclyn H Chu; Thomas J Walsh
Journal:  Pediatr Infect Dis J       Date:  2007-08       Impact factor: 2.129

View more
  4 in total

1.  Fulminant Rhizomucor pusillus mucormycosis during anti-leukemic treatment with blinatumomab in a child: A case report and review of the literature.

Authors:  Sarah Schober; Karin Melanie Cabanillas Stanchi; Anna Riecker; Matthias Pfeiffer; Ilias Tsiflikas; Gesa Wiegand; Leticia Quintanilla-Martinez; Susanne Haen; Martin Ebinger; Peter Lang; Rupert Handgretinger; Michaela Döring
Journal:  Med Mycol Case Rep       Date:  2020-12-29

2.  Rhizomucor pusillus Infection in a Patient with Acute Myeloid Leukaemia After Haematopoietic Stem Cell Transplantation: Clinical Impact of Metagenomics Next-Generation Sequencing.

Authors:  Lilin Liu; Huiqin Wu; Jianghong Liang; Wenhao Wu; Ye Peng; Hua Zhou; Xi Li
Journal:  Infect Drug Resist       Date:  2022-08-06       Impact factor: 4.177

3.  Invasive Fusariosis in the Voriconazole Era: Single-Center 13-Year Experience.

Authors:  Jessica M Stempel; Sarah P Hammond; Deanna A Sutton; Linda M Weiser; Francisco M Marty
Journal:  Open Forum Infect Dis       Date:  2015-07-04       Impact factor: 3.835

Review 4.  Epidemiology and Diagnosis of Mucormycosis: An Update.

Authors:  Anna Skiada; Ioannis Pavleas; Maria Drogari-Apiranthitou
Journal:  J Fungi (Basel)       Date:  2020-11-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.